[Federal Register Volume 84, Number 183 (Friday, September 20, 2019)]
[Notices]
[Page 49555]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-20414]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Fisher Clinical 
Services, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before October 21, 2019. 
Such persons may also file a written request for a hearing on the 
application on or before October 21, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on July 19, 2019, Fisher Clinical Services, Inc., 700A-C 
Nestle Way, Breinigsville, Pennsylvania 18031-1522 applied to be 
registered as an importer of the following basic classes of controlled 
substances:

------------------------------------------------------------------------
         Controlled substance           Drug code         Schedule
------------------------------------------------------------------------
Psilocybin............................       7437  I
Methylphenidate.......................       1724  II
Levorphanol...........................       9220  II
Noroxymorphone........................       9668  II
Tapentadol............................       9780  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances for 
clinical trials.

    Dated: August 19, 2019.
Neil D. Doherty,
Acting Assistant Administrator.
[FR Doc. 2019-20414 Filed 9-19-19; 8:45 am]
BILLING CODE 4410-09-P